651 related articles for article (PubMed ID: 14993502)
21. Efficacy and safety of low-dose chlorambucil in nephrotic patients with idiopathic membranous nephropathy.
Idasiak-Piechocka I; Oko A; Łochyńska-Bielecka K; Skrobańska B
Kidney Blood Press Res; 2009; 32(4):263-7. PubMed ID: 19776643
[TBL] [Abstract][Full Text] [Related]
22. The therapy of idiopathic membranous glomerulonephritis.
Glassock RJ
Semin Nephrol; 1991 Mar; 11(2):138-47. PubMed ID: 2034923
[TBL] [Abstract][Full Text] [Related]
23. Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy.
Naumovic R; Furuncic D; Jovanovic D; Stosovic M; Basta-Jovanovic G; Lezaic V
Biomed Pharmacother; 2010 Nov; 64(9):633-8. PubMed ID: 20888177
[TBL] [Abstract][Full Text] [Related]
24. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
Pozzi C; Del Vecchio L; Locatelli F
G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
[TBL] [Abstract][Full Text] [Related]
25. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment.
Polanco N; Gutiérrez E; Rivera F; Castellanos I; Baltar J; Lorenzo D; Praga M;
Nephrol Dial Transplant; 2012 Jan; 27(1):231-4. PubMed ID: 21624942
[TBL] [Abstract][Full Text] [Related]
26. Idiopathic membranous nephropathy in the elderly.
Passerini P; Como G; Viganò E; Melis P; Pozzi C; Altieri P; Ponticelli C
Nephrol Dial Transplant; 1993; 8(12):1321-5. PubMed ID: 8159299
[TBL] [Abstract][Full Text] [Related]
27. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
[TBL] [Abstract][Full Text] [Related]
28. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
du Buf-Vereijken PW; Branten AJ; Wetzels JF
Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine A in treatment of membranous lupus nephropathy.
Hu W; Liu Z; Shen S; Li S; Yao X; Chen H; Li L
Chin Med J (Engl); 2003 Dec; 116(12):1827-30. PubMed ID: 14687467
[TBL] [Abstract][Full Text] [Related]
30. Conventional treatment of idiopathic nephrotic syndrome and membranous nephropathy in adults.
Ponticelli C; Passerini P
Clin Nephrol; 1991; 35 Suppl 1():S16-21. PubMed ID: 1860261
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive treatment of Berger's disease.
Faedda R; Pirisi M; Satta A; Bosincu L; Bartoli E
Clin Pharmacol Ther; 1996 Nov; 60(5):561-7. PubMed ID: 8941029
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria.
Passerini P; Pasquali S; Cesana B; Zucchelli P; Ponticelli C
Nephrol Dial Transplant; 1989; 4(6):525-9. PubMed ID: 2507973
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppressive therapy with cyclophosphamide and prednisolone in severe idiopathic membranous nephropathy.
Kibriya MG; Tishkov I; Nikolov D
Nephrol Dial Transplant; 1994; 9(2):138-43. PubMed ID: 8190328
[TBL] [Abstract][Full Text] [Related]
34. Idiopathic membranous glomerulonephritis: long-term follow-up in 139 cases.
Murphy BF; Fairley KF; Kincaid-Smith PS
Clin Nephrol; 1988 Oct; 30(4):175-81. PubMed ID: 3214963
[TBL] [Abstract][Full Text] [Related]
35. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
[TBL] [Abstract][Full Text] [Related]
36. [The late results of treating membranous glomerulonephritis].
Belovezhdov N; Robeva R; Dimitrova V
Vutr Boles; 1990; 29(3):53-60. PubMed ID: 2284800
[TBL] [Abstract][Full Text] [Related]
37. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
39. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy.
McQuarrie EP; Stirling CM; Geddes CC
Nephrol Dial Transplant; 2012 Jan; 27(1):235-42. PubMed ID: 21558430
[TBL] [Abstract][Full Text] [Related]
40. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy.
Heeringa SF; Branten AJ; Deegens JK; Steenbergen E; Wetzels JF
Nephrol Dial Transplant; 2007 Aug; 22(8):2201-7. PubMed ID: 17442739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]